After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Acadia Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $3.33B. A total of 1.21 million shares were traded on the day, compared to an average of 2.46M shares.
In the most recent transaction, Teehan Brendan sold 10,329 shares of ACAD for 16.81 per share on Nov 19 ’24. After the transaction, the EVP, COO, HEAD OF COMMERCIAL now owns 62,105 company shares. In a previous transaction on Nov 19 ’24, Kihara James sold 4,073 shares at 16.81 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 19,863.
Among the insiders who sold shares, Schneyer Mark C. disposed of 10,259 shares on Nov 19 ’24 at a per-share price of $16.81. This resulted in the EVP, CHIEF FINANCIAL OFFICER holding 53,302 shares of ACAD after the transaction. In another insider transaction, Schneyer Mark C. sold 9,733 shares at $15.28 per share on Aug 19 ’24. Company shares held by the EVP, CHIEF FINANCIAL OFFICER now total 43,735.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ACAD has a high of $26.56 and a low of $14.15.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $3.47, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.00.
